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The luminal endoplasmic reticulum (ER) protein of 29 kDa (ERp29) is a ubiquitously
expressed cellular agent with multiple critical roles. ERp29 regulates the biosynthesis
and trafficking of several transmembrane and secretory proteins, including the
cystic fibrosis transmembrane conductance regulator (CFTR), the epithelial sodium
channel (ENaC), thyroglobulin, connexin 43 hemichannels, and proinsulin. ERp29 is
hypothesized to promote ER to cis-Golgi cargo protein transport via COP II machinery
through its interactions with the KDEL receptor; this interaction may facilitate the loading
of ERp29 clients into COP II vesicles. ERp29 also plays a role in ER stress (ERS)
and the unfolded protein response (UPR) and is implicated in oncogenesis. Here, we
review the vast array of ERp29’s clients, its role as an ER to Golgi escort protein, and
further suggest ERp29 as a potential target for therapies related to diseases of protein
misfolding and mistrafficking.
Keywords: endoplasmic reticulum, ERp29, chaperone, escort, Golgi, secretory pathway, trafficking, COP II

INTRODUCTION
The endoplasmic reticulum (ER) is a membrane bound organelle present in eukaryotic cells.
It is the site of co-translational synthesis of secretory proteins and membrane translocation
of transmembrane proteins (Barlowe and Miller, 2013). The nascent proteins that are being
synthesized and translocated into the ER lumen have unstable tertiary structures and heavily rely on
interaction with ER luminal molecular chaperones, a group of proteins that assist in protein folding,
to avoid misfolding and aggregation (Buck et al., 2007). Depending on the nascent luminal client,
ER chaperones may stabilize a client through binding to the lumen-exposed hydrophobic regions of
the nascent protein, catalyzing the formation of disulfide bridges, and/or by binding to the exposed
glycosyl side chain that was added to the nascent amino acid chain upon its entry into the ER
(lectin chaperones). With these functions as guidelines, ER luminal chaperones are often classified
into four groups: folding chaperones, that assist with protein folding, including the Protein
disulfide isomerase (PDI) and peptidyl-prolyl cis/trans isomerase (PPI) families; lectin chaperones,
including calnexin and calreticulin; general heat shock or stress-responsive chaperones, including
BiP/GRP78, GRP170, GRP94, and the non-classical molecular chaperones, including ERp29 and
HSP47 (Mahdi et al., 2016). The lack or imbalance of chaperone function due to mutations that
disrupt client interaction with chaperone(s), or transcriptional dysregulation, can lead to protein
aggregation within the ER and initiation of the unfolded protein response (UPR) (Mahdi et al.,
2016). Many ER chaperones have increased expression as a part of the UPR (Gomez-Navarro
and Miller, 2016), but, if this initial response is not successful in resolving or eliminating
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acts, we identified that a non-classical ER chaperone ERp29 is
upregulated in response to 4PBA treatment of CF bronchiolar
epithelial cells (Suaud et al., 2011a). Further studies by our
group demonstrated that ERp29 is required for proper biogenesis
of wild type CFTR, and that overexpression of ERp29 can
rescue the aberrant biosynthesis and trafficking of F508del
CFTR (Suaud et al., 2011a). These data identify ERp29 as
a novel drug target in a disease of aberrant protein folding
and trafficking.
ERp29 is ubiquitously expressed throughout the different
tissue types (Shnyder and Hubbard, 2002), especially in secretory
tissues, and is implicated in the biogenesis of many proteins
(Table 1). Our group’s work has demonstrated that ERp29
promotes CFTR maturation (Suaud et al., 2011a) and regulates
the maturation of the epithelial sodium channel (ENaC)
(Grumbach et al., 2014; Bikard et al., 2019) in epithelial cells. In
addition, our group’s recent data have suggested a role for ERp29
in regulating proinsulin biosynthesis (Viviano et al., 2020). These
data, and the potential general function of ERp29 suggested by its
wide variety of putative clients (Table 1) further emphasizes the
importance of understanding of the mechanism by which ERp29
contributes to the folding, trafficking, and function of these client
proteins. In this paper we will provide a comprehensive analysis
of ERp29 role as an essential ER to Golgi escort chaperone
by highlighting the effect ERp29 has on client biogenesis, and
by reviewing the potential role of ERp29 in client associated
disease etiology.

protein aggregates, apoptosis pathways will be activated to
eliminate the irreparably damaged cell (Mahdi et al., 2016).
Many secretory proteins require additional post-translational
modifications in the form of glycosylation, phosphorylation,
and protein cleavage in the Golgi Network (GN) to assume
their final, active conformations (Potelle et al., 2015). After a
secretory protein is fully synthesized and properly folded in
the ER, it is exported to the cis-Golgi, commonly via the Coat
Complex II (COP II) secretory vesicle pathway (Aridor et al.,
1998), and ER escort chaperones are often packaged into the
COP II vesicle together with their clients (Di Martino et al.,
2019). In the cis-Golgi, secretory proteins may dissociate from
the ER chaperone, potentially due to the more acidic pH of Golgi
compartment compared to ER, and ultimately continue through
the GN to undergo additional post-translational modifications
and maturation (Gomez-Navarro and Miller, 2016). In contrast
to the client protein, many of the ER chaperones are returned
to the ER via the Coat Complex I (COP I) retrieval pathway
(Gomez-Navarro and Miller, 2016). The majority of the luminal
ER chaperones contain a characteristic C-terminal ER retention
motif -K-D-E-L (Lys-Asp-Glu-Leu) (Pelham, 1990). This motif
functions to enforce retrieval of these ER chaperones from the
cis-Golgi via an interaction with the KDEL-Receptor (KDELR) and subsequent inclusion of this complex in COP I vesicles
(Yamamoto et al., 2001). The current understanding of the
KDEL-R role in the secretory protein pathway is limited to its
role in vesicle transport by COP I. However, there are recent
reports that observed KDEL-R at the plasma membrane of the cell
(Becker et al., 2016), as well as data supporting the hypothesis that
KDEL-R has a role in COP II-mediated ER→Golgi trafficking
(Bikard et al., 2019).
The dysregulation of nascent protein folding within the
ER, or dysregulation of protein transport from the ER to
the GN, is characteristic of many protein folding diseases,
including Cystic Fibrosis (CF), Alpha-1 Antitrypsin Deficiency,
Alzheimer’s Disease, Parkinson’s Disease, Type 2 Diabetes (T2D),
certain cancers, and others (Bartoszewski et al., 2008; Wang
and Kaufman, 2012). CF is caused by mutations in the Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR) gene
that encodes a chloride ion transporter typically found on
the apical surface of epithelial cells (Welsh and Smith, 1993).
CFTR biogenesis requires complex organization within the
membrane and folding in the ER, as well as further processing
in Golgi for CFTR to eventually assume its active form at the
apical plasma membrane (Kim and Skach, 2012). The most
common disease-causing CFTR mutation is F508del (an inframe deletion of Phenylalanine 508), which primarily results
in a mutant CFTR protein that is poorly folded and does not
exit the ER (Lukacs and Verkman, 2012). Recent developments
in therapy for CF, including those aimed at restoring proper
biosynthesis of F508del, have dramatically improved clinical
outcomes for people with CF (Lopes-Pacheco, 2019). One
of the earliest small molecules that was demonstrated to
improve F508del CFTR trafficking to the plasma membrane,
and function is sodium 4-phenylbutyrate (Buphenyl , 4PBA)
(Rubenstein et al., 1997; Rubenstein and Zeitlin, 1998). In
our group’s interrogation of the mechanism by which 4PBA

ERp29 Structure
ERp29 is a member of the ER luminal protein disulfide
isomerase (PDI) chaperone family and contains four distinct
domains (Ferrari et al., 1998). These include the N-terminal ER
localization domain/signal sequence that is cleaved upon entry
into the ER, the b-type PDI domain, the D-domain, and an ER
retrieval KEEL (Lys-Glu-Glu-Leu) domain at the C-terminus.
Although ERp29 contains a conserved thioredoxin-like PDI
domain, it is classified as a “non-classical” chaperone as this
domain, and holo-ERp29, contains only a single Cysteine and
does not possess any thioredoxin enzymatic activity (Ferrari
et al., 1998; Galligan and Petersen, 2012). Nevertheless, ERp29
has several hydrophobic protein binding domains on its surface,
and facilitates protein folding and ER export by interacting
with multiple clients and other chaperones in the ER lumen
(Barak et al., 2009; Nakao et al., 2017).
Insight into the structural and functional domains of
human ERp29 can be inferred from studies of homologs
and paralogs from other species, including rat and mouse
ERp29, and Drosophila melanogaster Windbeutel (Wind). Wind
expression in Drosophila is essential for the transport of
Pipe, a glycosaminoglycan-modifying enzyme with homology
to heparan sulfate 2-O-sulfotransferase in mammals (Sergeev
et al., 2001), to the Golgi where it regulates dorsal-ventral
embryogenesis of D. melanogaster embryos via an extracellular
serine protease cascade (Sen et al., 2000). When Pipe is
expressed in tissues without Wind, Pipe remains in the ER and
embryo dorsal-ventral patterning does not occur; this results in
embryonic death (Sen et al., 2000). Unlike mammalian ERp29,
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TABLE 1 | ERp29 clients and implications in disease.
ERp29 client

Function

Disease implications

References

Epithelial sodium channel
(ENaC)

Epithelial sodium channel regulates airway
surface liquid volume, sodium concentration,
blood volume, blood pressure

Liddle’s syndrome,
pseudohypoaldosteronism, hypertension

Grumbach et al., 2014

Cystic fibrosis transmembrane
conductance regulator (CFTR)

ABC transporter of chloride ions in epithelia
regulates sodium and water balance

Cystic fibrosis (CF)

Cormet-Boyaka et al., 2004; Suaud et al.,
2011a

(Pro)insulin

Peptide hormone. Regulator of blood
glucose levels

Type two diabetes (T2D)

Smeekens et al., 1992; Nishigori et al., 1996;
Viviano et al., 2020

Thyroglobulin (Tg)

Thyroid hormone (T3 and T4 ) precursor

Goiter, hypothyroidism

Sargsyan et al., 2002a; Baryshev et al.,
2006; Citterio et al., 2013

Alpha-1 antitrypsin (A1AT)

Serpin protein protects tissues from
proteases

Liver failure, cirrhosis, chronic obstructive
pulmonary disease (COPD)

Sifers et al., 1988; Davis et al., 1990;
McElvaney et al., 2020

Alpha-1 type 1 collagen
(Collagen-I)

Structural protein in bone, scelera, skin, and
connective tissues

Osteogenesis imperfecta (OI),
Ehlers-Danos syndrome (EDS)

Byers and Steiner, 1992; Myllyharju and
Kivirikko, 2001; DiChiara et al., 2016; Miller
and Grosel, 2020

Connexin-43 (Cx43)

Gap junction alpha-1 protein

Oculodentodigital dysplasia (ODDD)

Paznekas et al., 2003; Bao et al., 2004;
Salameh, 2006; Laird, 2008; Das et al., 2009

PKR-like endoplasmic
reticulum kinase (PERK,
EIFA2K3)

Transcription factor phosphorylates
α-subunit of EIF2 to repress transcription in
ER stress conditions

Wollcott-Rallison syndrome

Julier and Nicolino, 2010; Farmaki et al.,
2011

ATP-binding cassette
transporter-1 (ABCA1)

ABC transporter of lipids. Lipid removal
pathway component.

Tangier disease, high density lipoprotein
(HDL) deficiency

Schmitz and Langmann, 2001; Sorrenson
et al., 2013

ATP-binding cassette
transporter-3 (ABCA3)

ABC transporter of lipids. Lipid removal
pathway component.

Fatal respiratory distress syndrome
(RDS), cataract microcornea syndrome,
surfactant metabolism dysfunction type-3

Cheong et al., 2006; Beers and Mulugeta,
2017

Activating transcription
factor-6 (ATF6)

Transcription factor. Transported to and
cleaved in Golgi upon ER stress.

Cancer

Hirsch et al., 2014

the D. melanogaster Wind protein has a conserved (C-X-XC) PDI domain (Ma et al., 2003). The important structural
and functional homology of the C-terminal D-domain between
Wind and human ERp29 (Ma et al., 2003), allowed for better
characterization of ERp29 function in earlier studies.
The generation of high resolution crystal protein structure
of human ERp29 was delayed by increased domain mobility in
the structure due to the presence of a longer linker between
N-terminal b-domain and the C-terminal D-domain in human
compared to mouse and D. melanogaster, 7 versus 2 amino acids,
respectively (Figure 1A) (Barak et al., 2009). All mammalian
ERp29 proteins lack a classical thioredoxin (C-X-X-C) motif
and therefore lack such thioredoxin function (Ferrari et al.,
1998; Ma et al., 2003). At the same time the in vitro and
in vivo studies of ERp29 protein–client interactions demonstrated
that the D-domain located in the C-terminal half of ERp29 is
highly conserved between species and required for client binding
and processing (Lippert et al., 2007). In vitro studies of Wind
demonstrated that this chaperone has binding affinity for clients
with Tyrosine (Y) and Phenylalanine (F) aromatic residues, either
adjacent (e.g., –(F,Y)-(F,Y)-) or separated by a single amino
acid (e.g., –(F,Y)-X-(F,Y)-) (Barnewitz et al., 2004). A similar
client binding affinity has been suggested for mammalian ERp29
(Barak et al., 2009).
The hydrodynamic properties of human ERp29 suggest
that the protein assumes a homodimeric tertiary structure
(Hermann et al., 2005). This homodimerization occur through
an interaction of two N-terminal ERp29 domains (Barak
et al., 2009). In D. melanogaster, Wind dimerization creates a
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negatively charged acidic cleft; this cleft is required for client
interaction (Barnewitz et al., 2004). However, the cleft formed by
homodimerization of the b-domain of mammalian ERp29 lacks
similar biochemical characteristics, and cannot bind Wind clients
(Hermann et al., 2005). That said, ERp29 dimerization is essential
for its function as an ER chaperone (Rainey-Barger et al., 2007).
Further characterization of the ERp29 dimer cleft is required to
further elucidate its function as a chaperone and escort protein.
The tightly bound, non-globular, dimeric structure of ERp29
places the two C-terminal D-domains on the opposite sides of
an elongated complex (Figure 1B) (Hermann et al., 2005). This
structure suggests that the ERp29 homodimer may serve as a
linker that coordinates a larger hetero-complex of chaperones,
its clients, and ER export machinery (Meunier et al., 2002). The
proper folding of the D-domain is essential for ERp29 function
(Lippert et al., 2007). The N-terminal and C-terminal domains of
ERp29 are joined with a hydrophobic linker. This linker shares
a conserved Cysteine residue at the beginning of the D-domain.
Mutation of this residue (human C157S) affects hydrophobic
characteristics of the linker and disrupts the function of ERp29
homodimer (Hermann et al., 2005). In our discussion below,
we will address the functional effects of this C157S mutation on
client protein binding and chaperone function in vivo.

Shuttling of ERp29 Between the ER and
Golgi
The retrograde and anterograde vesicular transport of cargo
proteins between the ER and the cis-Golgi network is controlled
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FIGURE 1 | ERp29 structure. (A) The structural alignment of ERp29 protein functional domains from human, mouse, and Drosophila melanogaster. (B) Cartoon of
the proposed ERp29 complex at the ER membrane (partially created with BioRender.com). The color scheme between (A,B) is consistent, demonstrating ERp29
dimerization at the N-terminus domain interface and serving as a linker of a larger protein complex.

by COP I and COP II machinery, respectively (Figure 2).
COP II trafficking is of particular relevance to secretory protein
biogenesis as it is major trafficking machinery of the early
secretory pathway. The COP II complex, or COP II machinery,
is comprised of the heteromeric protein complexes Sec23-Sec24
and Sec13-Sec31, the assembly and disassembly of which is
regulated by the Sar1 GTPase (Figure 2). Sar1-GDP is activated
to Sar1-GTP via Sec12, a transmembrane guanine nucleotide
exchange factor (GEF) located on the luminal face of the
ER membrane. It is constitutively active, as it displays GEF
activity in reactions containing only Sar1, GTP, and synthetic
phospholipids, though its GEF activity can be enhanced by
potassium (Futai et al., 2004; McMahon et al., 2012). For larger
secreted cargo (e.g., collagen), Sec12 is concentrated at the site
of COP II vesicle formation. In the specific case of collagen,
Sec12 is concentrated at the site by cutaneous T-cell lymphomaassociated antigen 5, or cTAGE5 (a component of the collagen
cargo receptor) to increase nucleotide exchange on Sar1 (Saito
et al., 2014). From there, Sar1-GTP and Sec23-Sec24 interact to
recruit the additional cargo proteins to the emerging COP II
vesicle. Sec24 has four isoforms and is the main cargo recognition
adaptor of COP II machinery; these cargoes often contain
recognition motifs including di-acidic motifs (e.g., D-X-E, D-XD) or large C-terminal di-hydrophobic or di-aromatic motifs
(e.g., FF, YY, and/or FY); these motifs are crucial for cargo exit
from the ER via COP II vesicles (Votsmeier and Gallwitz, 2001;
Barlowe, 2003). Sec13-Sec31 then binds to the growing COP II
unit and causes the budding of the COP II vesicle. The Sec13Sec31 complex also recruits other Sar1/Sec23-Sec24 complexes to
the budding vesicle, which further concentrates proteins targeted
for ER exit. At the cis-Golgi, Sec23 promotes hydrolysis of GTP
by Sar1 and return to its inactive Sar1-GDP form; this facilitates
disassembly of the COP II complex.
The KDEL receptor (KDEL-R) regulates the retrograde
trafficking of proteins containing a C-terminal ER retention
signal from the cis-Golgi to the ER via COP I transport
machinery. KDEL-R has three isoforms (1, 2, and 3)
that are G-protein coupled-like receptors of the PQ-loop
superfamily with seven transmembrane spanning helices

Frontiers in Physiology | www.frontiersin.org

(Giannotta et al., 2012; McMahon et al., 2012). These receptors
primarily interact with C-terminal -K-D-E-L motifs in higher
eukaryotes, or -H-D-E-L motifs in yeast. This process is pH
dependent, with the low pH of the Golgi (∼6) enhancing the
interaction between the KDEL-R and the KDEL motif; the
relatively neutral pH of the ER (∼7.2–7.4) promotes release of
the protein from the KDEL-R (Scheel and Pelham, 1996; GomezNavarro and Miller, 2016; Bräuer et al., 2019). Presumably, to
fulfill this function, the KDEL-R must get to the cis-Golgi via
COP II transport. However, a function for the KDEL-R in this
anterograde movement is less well-demonstrated. Furthermore,
there are no well-defined unique functions for the different
isoforms of KDEL-R, although some recent data suggesting
KDEL-R2 and KDEL-R3 play a role in controlling the UPR
(Trychta et al., 2018). KDEL-R2 and KDEL-R3, but not KDELR1, were found to have increased expression in SH-SY5Y,
INS-1, 832/13, HEK293, and rat primary cortical neurons after
Ca2 + depletion of the ER using thapsigargin and after ER stress
induction by tunicamycin. Additionally, KDEL-R2 and KDELR3 expression was increased after addition of the transcription
factor XBP1, a known regulator of ER stress proteins (e.g., Erdj4)
in HEK293 cells; in silico studies also suggested putative binding
sites for XBP1 on the promoters for KDEL-R2 and -R3, but not
-R1. There are also some data suggesting a role for KDEL-R1 in
protein recognition and endocytosis on the plasma membrane in
HeLa cells (Becker et al., 2016; Trychta et al., 2018). KDEL-R1
was found at the cell surface and was shown to be crucial in
allowing fluorescent markers with an -H-D-E-L tag to gain entry
into the cytoplasm. Taken together, these data further suggest a
role for KDEL-R at sites in the secretory pathway more distal to
the cis-Golgi.
With regards to the KDEL-R having a role in anterograde
ER→Golgi trafficking via COP II, our group has recently
found that ERp29 likely interacts with KDEL-R1 as part of
the anterograde trafficking of the epithelial sodium channel
(ENaC) in CFBE41o- CF bronchial epithelial cells and MDCK
renal epithelial cells (Bikard et al., 2019). Furthermore, we
demonstrated that deletion of ERp29’s C-terminal -K-E-E-L ER
retention motif (a KDEL homolog) reduced the interaction
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FIGURE 2 | ERp29 in protein trafficking. Schematic representation of ERp29 role in ER to Golgi secretory pathway (image created with BioRender.com).

motifs, with KDEL-R2 having a more narrow specificity than
KDEL-R1 or -R3 (Raykhel et al., 2007). In addition, Raykhel et al.
(2007) demonstrated that 45 different KDEL-like motifs resulted
in ER retention in HeLa cells; when any of these KDEL-like motifs
were not present, predominant localization to the Golgi was the
almost exclusive result. Interestingly, a KXEL motif caused almost
exclusive localization in the ER, with the “X” amino acid being
polar, charged, or hydrophobic.

of ENaC with the Sec24D as seen in co-immunoprecipitation
experiments (CFBE41o- and MDCK cells). Similar effects on
ENaC biogenesis were observed with depletion of KDEL-R1
or Sec24D (Bikard et al., 2019). Taken together, these data
suggest ERp29, through an interaction with KDEL-R1, regulates
ENaC biogenesis, which indicates a novel role for KDEL-R1 in
anterograde protein trafficking.
As mentioned above, ERp29 contains a C-terminal KEEL
motif that interacts with the KDEL-R rather than the more
classical C-terminal KDEL motif. KEEL-harboring ER
constituents are less fully retained in the ER than those
with KDEL; in other words, KEEL binding has lower affinity than
KDEL to KDEL-R in the acidic Golgi (Giannotta et al., 2012;
Stevens et al., 2019). In fact, our group has found ERp29 in more
distal compartments, including at the surface of epithelial cells
and secreted into culture media in CFBE41o- cells (Suaud et al.,
2011a), suggesting that ERp29 may have other functional roles
beyond promoting anterograde ER → Golgi trafficking of client
cargo via KDEL-R and COP II machinery.
In addition to KEEL, there are other KDEL-like motifs
described in the literature. Some evidence suggests that the
KDEL-R isoforms preferentially bind to different KDEL-like

Frontiers in Physiology | www.frontiersin.org

ERp29 and the ER Stress Response
As with other ER resident chaperones such as BiP/Grp78,
ERp29 expression is upregulated during ER stress (ERS) and the
unfolded protein response (UPR) in both pancreatic beta cells
and thyroid epithelial cells (Sargsyan et al., 2004; Gao et al., 2016);
however, its role in ERS and UPR remains somewhat unclear
(Farmaki et al., 2011). That ERp29 expression is elevated in
some tumors or when genotoxic stress is induced with ionizing
radiation (Zhang et al., 2008; Farmaki et al., 2011) may suggest
a broader role for ERp29 in stress conditions, and perhaps
in apoptosis. Additionally, ERp29 is upregulated by treatment
with doxorubicin, an anti-neoplastic chemotherapeutic drug,
in a p53-dependent manner in PC3 prostate cancer cells and
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increased expression of key chaperones and pro-survival factors
implicated in ERS, including BiP/GRP78 itself (Malhotra and
Kaufman, 2007). Specifically, PERK phosphorylates and activates
the translation-inhibiting protein, eIF2α, resulting in a global
decrease in protein translation (Malhotra and Kaufman, 2007).
While it is logical to hypothesize that ERp29 is predominantly
upregulated during ERS to facilitate stabilization of its clients for
their eventual exit from the ER, there are also data suggesting that
ERp29 may play a role in the underlying pathways that regulate
and facilitate UPR and ERS. For example, siRNA-mediated
knockdown of ERp29 during induced ERS was associated with
decreased expression of BiP mRNA in INS1 rat pancreatic
beta cells (Gao et al., 2016). Furthermore, ERp29 associates
with PERK in co-precipitation studies (Farmaki et al., 2011;
Gao et al., 2016), and increased ERp29 expression results
in upregulated intracellular PERK levels, as well as increased
phosphorylation/activation of its downstream target, eIF2α. On
the other hand, overexpression of the ERp29 C157S mutant did
not result in a similar increase of PERK levels, and interestingly,
decreased the activation of eIF2α as compared to non-transfected
controls (Farmaki et al., 2011). Taken together, these data
suggest a direct role for ERp29 in UPR regulation that may be
dependent on its interaction with PERK, perhaps by facilitating

Mouse Embryonic Fibroblasts (Farmaki et al., 2011). However,
upregulation of ERp29 expression is also observed when ERS
is present in both thyroid cells and INS1 pancreatic β-cells
(Sargsyan et al., 2004; Gao et al., 2016), and in lactating mammary
gland cells compared to resting glands (Mkrtchian et al., 2008). It
is thus hypothesized that ERp29’s involvement in UPR is limited
to its role as a chaperone for secretory proteins (Sargsyan et al.,
2004; Mkrtchian et al., 2008; Farmaki et al., 2011), which is
consistent with ERp29 being most highly expressed in secretory
cells (Sargsyan et al., 2002a). This role for ERp29 in ERS is
consistent with the hypothesis that ERp29 is critical in facilitating
the exit of clients from the ER via COP II vesicles.
Under conditions of ERS, the UPR is initiated by the activation
of three proteins that are both sensors of ER stress and regulators
of the subsequent response: the transcription factor, ATF6, and
two kinases, IRE1 and PERK (Figure 3) (Malhotra and Kaufman,
2007). Under resting circumstances, ATF6, IRE1, and PERK
associate with and are “sequestered” in the ER by BiP/GRP78.
In the presence of unfolded protein in the ER, BiP/GRP78
preferentially binds to the unfolded protein, thereby releasing
ATF6, IRE1 and PERK to activate the UPR. The subsequent
actions of these three sensor proteins when released from
BiP/GRP78 lead to downregulation of protein translation and

FIGURE 3 | ERp29 role in the unfolded protein response (UPR). Schematic representation of UPR pathways, highlighting the potential site of ERp29 action (image
created with BioRender.com).

Frontiers in Physiology | www.frontiersin.org
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ER (Burrows et al., 2000; Mueller et al., 2007). Similarly, we
demonstrated that depletion of Sec24D protein expression
reduces the number of cleaved subunits on the cell surface but
does not reduce the amount of β-ENaC at the cell surface. These
data suggest that when the COP II ER exit pathway is blocked,
ENaC can still reach the plasma membrane by a non-COP II
pathway that allows the channel to bypass cleavage by furin in
the Golgi or later compartments (Bikard et al., 2019).
Interestingly, ERp29 also appears to direct ENaC to the Golgi
for cleavage of its α and γ subunits during biogenesis, as both
depletion of ERp29 protein expression and expression of a
mutant ERp29 with its single cysteine changed to serine (ERp29
C157S) have the same effect as depletion of Sec24D (Grumbach
et al., 2014). Similarly, our group’s more recent data suggest
that an interaction of ERp29 with the KDEL-R is required to
promote transport of ENaC through COP II vesicles from the
ER to the Golgi to facilitate the cleavage of α- and γ-ENaC
(Bikard et al., 2019). Both deleting ERp29’s C-terminal KEEL
motif, which should interrupt ERp29’s interaction with KDELR, and depletion of the expression of KDEL-R1 decreased both
association of β-ENaC with Sec24D and levels of cleaved, active
ENaC at the cell surface, again without altering total ENaC at
the cell surface. Together, these data from our group suggest that
ERp29, at least in part through an interaction with KDEL-R1,
promotes inclusion of nascent ENaC into COP II vesicles for
transport to the Golgi where α and γ undergo cleavage by furin
in the trans-Golgi or later compartments. It is also possible that,
because its KEEL ER retention motif that has lower affinity for the
KDEL-R than KDEL in the cis-Golgi, ERp29 more readily escapes
ER retention by dissociating from KDEL-R in the cis-Golgi,
and then accompanies or escorts ENaC to the trans-Golgi to
“directly” facilitate ENaC cleavage (Gomez-Navarro and Miller,
2016; Bräuer et al., 2019). This would provide one hypothetical
mechanism by which ENaC that is not associated with ERp29
could bypass such Golgi processing.

the interaction of PERK with its downstream client, eIF2α
(Farmaki et al., 2011; Gao et al., 2016). Future studies should
aim to further elucidate ERp29’s role in UPR, as this response
plays a key role in the underlying pathophysiology of cancer and
many other diseases, including those of secretory cells such as
the insulin-secreting β-cells in Type II diabetes (Ozcan et al.,
2004; Sundar Rajan et al., 2007). Additionally, it is currently
unclear how erp29 expression is regulated during ERS and UPR.
Future work should aim to identify potential ER stress responsive
elements in the erp29 promoter or IRES sequences that allow
preferential translation of erp29 mRNA during ERS.

ERp29 and Transmembrane Protein
Biogenesis
As mentioned above, our interest in ERp29 derived from studies
of the mechanism by which 4PBA rescues F508del CFTR
trafficking in CF epithelia (Rubenstein et al., 1997; Rubenstein
and Zeitlin, 1998, 2000; Rubenstein and Lyons, 2001; Suaud
et al., 2011a,b). Upon identification of ERp29 potentially playing
a role in this process, we extended these studies to test the role
of ERp29 in the biogenesis of ENaC (Grumbach et al., 2014;
Bikard et al., 2019), another epithelial ion channel relevant to
CF. In this section, we will discuss ERp29’s role in regulating the
transmembrane proteins biogenesis.

Epithelial Sodium Channel (ENaC)
ENaC is a heterotrimer comprised of three similar subunits: α,
β, and γ; alternate δ-ENaC channels found in some epithelia
substitute a δ subunit for the α subunit (Giraldez et al., 2012).
The three subunits presumably assemble in the ER before they
are transferred to the Golgi by means of COP II machinery for
maturation of N-glycosylation and furin-mediated cleavage of
the α and γ subunits; the cleavage process may occur in the
Golgi or later compartments. From there, the protein complex
is brought to the plasma membrane where the channels play an
important role in Na+ resorption in various epithelia, including
the airway and renal collecting duct. Full cleavage of the α
and γ subunits is associated with the channel having a high
(∼1.0) open probability. Interestingly, some ENaC bypasses these
Golgi modifications and arrives at the plasma membrane via an
alternative pathway in a core glycosylated, uncleaved, low (∼0)
open probability form. The most common clinical condition
associated with ENaC is Liddle’s syndrome, a disease caused by
constitutively active ENaC that has impaired retrieval from the
apical plasma membrane (Schild et al., 1995). ENaC hyperactivity
is also seen in cystic fibrosis patients as a result of its dysregulation
caused by mutations in the cystic fibrosis transmembrane
regulator (CFTR) protein (Kunzelmann et al., 2001).
We demonstrated that the Sec24D cargo recognition
component of COP II machinery plays a pivotal role in directing
ENaC from the ER to the Golgi for further processing in
CFBE41o- and MDCK cells (Grumbach et al., 2014). Sec24D
likely interacts with the C-terminus of α-ENaC, as deletion
of a 5 amino acid sequence (R-S-R-Y-W) within this region
prevents ENaC from leaving the ER; removal of the C-termini
of the β and γ subunits still allows exit of ENaC from the
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Cystic Fibrosis Transmembrane
Conductance Regulator (CFTR)
As is typical for N-glycosylated transmembrane proteins,
including ion channels, CFTR is transported from the ER
to the Golgi with “immature” high mannose-type N-linked
glycans; “maturation” of these glycans then occurs in the
Golgi by enzymatic modification. For CFTR, this maturation
is biochemically assessed as a change from “band B,” having
Endoglycosidase H-sensitive N-linked glycosylation indicative of
processing in the ER, to a higher molecular weight “band C”
harboring glycans that have been modified in the Golgi and
are now resistant to release with Endoglycosidase H (CormetBoyaka et al., 2004). The F508del CFTR mutant protein does
not undergo this normal glycosyl maturation, indicative of
impaired ER→Golgi transport, and does not reach the apical
surface of epithelia (Cheng et al., 1990; Riordan, 1999). F508del
also has reduced interaction with the Sec24D cargo recognition
component of COP II ER exit machinery in HEK293 cells (Wang
et al., 2004), further suggesting that its ER→Golgi transport is
impaired. F508del that does not exit the ER is degraded via
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ABCA1 and ABCA3 lipid transporters that cause their retention
in the ER can be rescued with 4PBA at similar concentrations
to that used to rescue F508del CFTR. As CFTR is also a
member of the ABC transporter family (CFTR is ABCC7), it is
logical to hypothesize that the rescue of ABCA1 and ABCA3 by
4PBA may result from a similar mechanism involving increased
ERp29 expression. Similarly, a mutation in the bile salt export
pump BSEP/ABCB11 that causes ER retention is also rescued
by 4PBA in MDCK cells (Hayashi and Sugiyama, 2007). Similar
effects of 4PBA are seen in neuronal cells, with 4PBA rescuing
misfolded creatine transporter-1 (CTR-1) channels from the ER
and allowing their trafficking to the cell surface in HEK293
cells (El-Kasaby et al., 2019). Finally, 4PBA also restores cell
surface expression of monocarboxylate transporter 8 (MCT8, a
thyroid hormone transporter) in patients with Allan-HerndonDudley syndrome, a condition characterized by mutations in
MCT8 resulting in retention of the transporter in the ER
(Braun and Schweizer, 2017).
Taken together, the similarities of F508del CFTR and the
trafficking mutations of these other mutant transporters that
are rescued by treatment with 4PBA, and 4PBA’s known effect
of increasing ERp29 mRNA and protein levels, suggests the
hypothesis that ERp29 may play a common role in the biogenesis
of these transmembrane channel/transporter proteins. Significant
work will be required to more thoroughly test this hypothesis.

ubiquitination and ER associated degradation (ERAD) (Ward
et al., 1995; Lukacs and Verkman, 2012).
Our group’s earlier studies of the mechanism by which 4phenylbutyrate (4PBA) rescues F508del trafficking and function
in IB3-1 CF bronchiolar epithelial cells concentrated on 4PBA’s
regulation of the cytosolic 70 kDa heat shock protein chaperones
Hsc70 and Hsp70 (Yang et al., 1993; Rubenstein and Zeitlin,
2000; Rubenstein and Lyons, 2001; Suaud et al., 2011b). However,
a primarily cytosolic mechanism of action for the effects of
4PBA would seemingly not be applicable to primarily ER luminal
cargoes such as PiZ Alpha-1 antitrypsin (A1AT) where 4PBA
also has positive effects in model systems (see discussion below)
(Burrows et al., 2000; Greene and McElvaney, 2010). Thus, when
we found that 4PBA also caused increased ERp29 mRNA and
protein expression (Suaud et al., 2011a), we began to focus on this
non-classical ER chaperone as potentially mediating a common
mechanism for improvement in trafficking of proteins that are
retained in the ER.
In fact, our group’s work demonstrates that wild type CFTR
maturation from the ER through the Golgi and its function at
the cell surface can be reduced by depleting ERp29 expression
in IB3-1 cells and T84 colonic adenocarcinoma cells; these
data were the first to describe a positive role for an ER
chaperone in CFTR biogenesis. Furthermore, we demonstrated
that overexpression of ERp29 can rescue F508del trafficking and
restore its expression at the surface of epithelial cells (Suaud
et al., 2011a). Interestingly, we found that ERp29 also traverses
this vesicular trafficking/secretory pathway, as it is found both
at the cell surface and in the conditioned media, suggesting that
ERp29 may accompany or escort clients through more distal
compartments (Suaud et al., 2011a).
CFTR contains exactly one putative ERp29 interaction motif
on its luminal extracellular face, 1013 P-Y-I-F1016 , on extracellular
loop 5. Furthermore, there are naturally occurring diseasecausing mutations within or adjacent to this motif described
(Y1014C, F1016S, P1013H, and P1013L) (Cystic Fibrosis Centre
at the Hospital of Sick Children in Toronto, 2020). These
mutations hypothetically lack the necessary or appropriately
conformed (in the case of the P1013 mutation at the end of
transmembrane helix 9) site for interaction with ERp29 and, thus,
may be unable to exit the ER.

ERp29 Role in Secretory Protein
Biosynthesis
As a chaperone of the ER lumen, ERp29 is demonstrated to
associate with and influence the biosynthesis of a number of
diverse secretory proteins. However, the mechanism(s) by which
ERp29 exerts these effects are not yet well-delineated. In this
section we review ERp29’s described clients that are secreted, as
well as glean mechanistic insight from these data.

Thyroglobulin (Tg)
Thyroglobulin (Tg) is a highly abundant iodinated glycoprotein
in the follicular thyrocytes of the thyroid gland, and is
the precursor to the thyroid hormones thyroxine (T4 )
and triiodothyronine (T3 ) (Pirahanchi et al., 2020). The
biosynthesis of Tg is complex, and several ER chaperones form
heterocomplexes with Tg in the thyrocyte ER. The ER chaperones
involved in Tg biosynthesis include ERp72, GRP94, BiP/GRP78,
PDI, calnexin, and ERp29 (Kuznetsov et al., 1994; Sargsyan
et al., 2002b; Park et al., 2005). Focusing specifically on ERp29,
immunoprecipitation of Tg from FRTL-5 thyrocytes treated
with chemical crosslinking reagents revealed Tg association with
ERp29, as well as with BiP/GRP78 and GRP94 (Sargsyan et al.,
2002b). Interestingly, ERp29 overexpression itself increased
expression of other Tg folding complex members, including
BiP/GRP78, calnexin, and PDI, suggesting a key role for ERp29
in the Tg protein folding complex that promotes Tg processing.
TSH (thyroid stimulating hormone that promotes T3 and T4
secretion) increases the expression of ERp29 (Kim and Arvan,
1993). Consistent with this, ERp29 and Tg colocalize in both
FRTL-5 and PCCL3 rat thyroid cells, and overexpression of

Other Transmembrane Proteins and
ERp29
ERp29 may be important in trafficking of other plasma
membrane channel or transporter proteins besides ENaC and
CFTR. This hypothesis is supported by ERp29 having abundant
expression in secretory cells (Shnyder and Hubbard, 2002)
(specifically related to channel proteins), as well as having
increased expression when cells are treated with 4PBA, a
treatment that can also rescue the impaired biogenesis of other
mutant transmembrane transport proteins.
For example, 4PBA increases surfactant protein secretion
caused by mutations in the lipid transporter proteins ATP
binding cassette A1 (ABCA1) and A3 (ABCA3) in HEK293 cells
(Cheong et al., 2006; Sorrenson et al., 2013). Mutations of the
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Disease due to A1AT deficiency primarily manifests in liver
and lung. In the liver, aggregation and polymerization of the
PiZ mutant in the hepatocyte ER may culminate in hepatocyte
death, liver failure and cirrhosis as early as the newborn
period (Patel and Teckman, 2018). Lack of protection from
neutrophil elastase in the lung with A1AT deficiency increases
lung susceptibility to injury, often manifesting clinically as
emphysema or chronic obstructive pulmonary disease (COPD)
(McElvaney et al., 2020).
Because PiZ A1AT is sequestered in the ER due to misfolding,
as is F508del CFTR (Cheng et al., 1990; Rubenstein et al., 1997),
the use of 4PBA to rescue PiZ secretion was explored. In fact,
4PBA improves the secretion of PiZ A1AT in both animal
models and cellular systems (Burrows et al., 2000). However,
this finding did not translate to significant clinical efficacy in
one small pilot human study using 4PBA as a rescue therapy
(Teckman, 2004). Even so, the preclinical data may suggest a
mechanistic commonality of 4PBA action on F508del and PiZ
through an increase in ERp29. Interestingly, A1AT contains a
188 Y-I-F-F191 motif and preliminary data from our laboratory
suggest ERp29 and A1AT may interact via this binding domain
in co-precipitation experiments in Madin-Darby Canine Kidney
(MDCK) and Cystic Fibrosis Bronchial Epithelial (CFBE41o-)
cells (unpublished data). ERp29’s role as a regulator of A1AT
biogenesis in the ER should be explored in the future to test
the hypothesis that ERp29 exercises a significant effect on
A1AT, and PiZ, protein folding, as well as subsequent liver
and lung pathology.

ERp29 in these cells increases Tg secretion nearly two-fold while
siRNA mediated knockdown of ERp29 reduces Tg expression and
arrests Tg secretion (Kwon et al., 2000; Sargsyan et al., 2002b).
In contrast, BiP/GRP78 or GRP94 overexpression decelerates
the maturation and folding of Tg in the ER and consequently
decreases Tg secretion (Muresan and Arvan, 1997).
Additional evidence for ERp29’s central role in Tg biosynthesis
comes from studies where mutation of ERp29’s conserved single
Cysteine residue, C157, to Alanine (C157A) or serine (C157S)
greatly reduced Tg secretion levels (Baryshev et al., 2006).
Similarly, mutation of a tyrosine residue conserved between
ERp29 and Wind (Y64S in ERp29) also reduced Tg secretion,
as did mutation of a solvent exposed Glutamine residue, Q70
(Q70A) (Ma et al., 2003; Baryshev et al., 2006).
Over 100 naturally-occurring mutations of the TG gene are
known with an incidence of approximately 1 in 100,000 newborns
(Targovnik et al., 2011; Citterio et al., 2013; Siffo et al., 2018).
Manifestations of these mutations include congenital goiter, low
serum Tg, high serum TSH, and hypothyroidism (Targovnik
et al., 2010). The most severe Tg-mutant disorders are associated
with Tg misfolding and sequestration within the ER (Citterio
et al., 2013; Morishita et al., 2020), including some Tg mutations
that cause defects in the export of Tg from the ER (Kim et al.,
1996; Rubio and Medeiros-Neto, 2009; Targovnik et al., 2010).
While the precise location of ERp29 binding on Tg is not known,
Tg has several -(F,Y)-X-(F,Y) and -(F,Y)-(F,Y)- motifs that are
consistent with other ERp29 clients (Barak et al., 2009), such
as CFTR and ENaC. However, there are currently no reported
naturally occurring mutations in Tg that disrupt the proposed
hydrophobic binding sites that ERp29 prefers in its other clients.
Given that upregulation of ERp29 increases the secretion of
Tg, enhancement of ERp29 function may be a potential target
for treatment of mutant-Tg associated disorders. Just as our
group has previously used sodium 4-phenylbutyrate (4PBA)
as a small molecule for F508del CFTR rescue (Suaud et al.,
2011b), 4PBA may be similarly able to rescue Tg secretion
by increasing ERp29 abundance. Future studies are needed to
identify other ERp29-centric therapies that rescue misfolded Tg
and promote its secretion.

Collagen-I
ERp29 was recently shown to have a novel protective function
in Type-I Collagen (collagen-I) synthesis. Collagen-I is the
most abundant collagen protein in humans and is the primary
structural component for skin and bone tissue (Shoulders and
Raines, 2009). Mutations in the collagen-I gene, COL1A1,
result in various collagenopathies, most notably osteogenesis
imperfecta (OI) and Ehlers-Danlos syndrome (EDS). OI and
EDS manifest as weakened bone structure and weakened or lax
connective tissue, respectively (Byers and Steiner, 1992; Miller
and Grosel, 2020). Notably, ERp29 has not been implicated as a
factor in diseases of collagen-I or related processes to date.
Collagen-I is heavily modified in both the ER and the
Golgi prior to secretion into the extracellular matrix. Recent
data implicate ERp29, ERp44, PDIA3, PDIA4, and EroL1 as
components of collagen-I’s proteostatic network in the ER
(DiChiara et al., 2016). While complex, collagen-I biosynthesis
includes the critical steps of the hydroxylation of various proline
and lysine residues (Yamauchi and Sricholpech, 2012; Miller and
Grosel, 2020). These hydroxylysines serve as attachment sites of
oligosaccharides and as sites of covalent crosslinking to provide
collagen-I it’s fibril strength (Yeowell and Walker, 2000), and
mutations in several ER-hydroxylases cause specific OI and EDS
disorders (Ha-Vinh et al., 2004; Yamauchi and Sricholpech, 2012).
These ER-resident hydroxylases require ascorbate for proper
function (Tajima and Pinnell, 1982; Franceschi et al., 1994) and
non-hydroxylated collagen-I is retained in the ER (Miller and
Grosel, 2020). Therefore, the presence of ascorbate promotes

Alpha-1 Antitrypsin (A1AT)
Alpha-1 antitrypsin (A1AT) is a secreted protease inhibitor that
impedes the unfettered action of serine proteases, most notably
neutrophil elastase in the lung. A1AT is encoded by SERPINA1,
and mutations in this gene result in A1AT deficiency. The most
common A1AT mutant, PiZ (E342K), causes A1AT retention
in the ER due to misfolding and polymerization of the nascent
protein (Sifers et al., 1988; Davis et al., 1990). The polymerization
of PiZ causes expansion of the ER, primarily in hepatocytes,
and reduced mobility of ER luminal chaperones, which may
impair their functionality; in some circumstances, this results in
hepatocyte death (Ordóñez et al., 2013). Another A1AT mutant,
Null Hong Kong (NHK, S343Rfs), also does not exit the ER but
does not polymerize and is instead subject to degradation by ER
associated degradation (ERAD) machinery (Zhong et al., 2015).
In contrast to PiZ, NHK has no effect on the mobility of ER
luminal chaperones (Davis et al., 1990).
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ERp29 promotes the assembly of functional hexameric Cx43
hemichannels in the Golgi of HeLa cells via stabilization of
Cx43 monomers in the ER and through their transport to
the Golgi (Das et al., 2009). Of relevance to this discussion,
treatment with 4PBA improved the ability of HeLa cells to process
overexpressed Cx43 into hemichannels; such overexpression
of Cx43 would otherwise saturate the processing system and
result in premature oligomerization of the monomers in the ER
(Asklund et al., 2004; Das Sarma et al., 2005, 2008). As 4PBA
increases ERp29 protein expression (Suaud et al., 2011a), further
experiments demonstrated that increased ERp29 expression
inhibited the premature oligomerization of Cx43 monomers in
the ER (Das et al., 2009). Furthermore, interfering with ERp29
function led to accumulation of Cx43 in the Golgi, decreased
Cx43 abundance at the plasma membrane, and impaired gap
junction communication as measured by intercellular transport
of fluorescent dye (Das et al., 2009). Taken together, these data
suggest that ERp29 stabilizes monomeric Cx43 in the ER and
prevents premature oligomerization, and thus plays a critical
role for the proper biogenesis and assembly of functional Cx43
hemichannels. Interestingly, the assembly of Cx43 hemichannels
in the Golgi requires formation of inter-subunit disulfide bonds,
a process that ERp29 cannot itself catalyze since it lacks the
thioredoxin domain that is typical of PDI-like proteins (Bao et al.,
2004; Mkrtchian et al., 2008). This characteristic of ERp29 may
suggest that it has evolved a specific role in stabilizing proteins
until later processing and/or disulfide bond formation.

proper collagen-I processing in the ER while in ascorbate
deficient conditions, the immature protein remains in the ER.
ERp29 may function to stabilize immature collagen-I in the ER
until it can be hydroxylated. Depletion of ERp29 does not affect
collagen-I secretion in ER-export conditions in the presence of
sufficient ascorbate. In contrast, depletion of ERp29 decreases
intracellular collagen-I and increases collagen-I secretion in ERretention conditions when ascorbate is deficient (Miller and
Grosel, 2020). Collagen-I and ERp29 may interact at one of
the several –(F,Y)-(F,Y)- or –(F,Y)-X-(F,Y)- motifs that are
present in collagen-I’s primary structure (Barak et al., 2009).
Interestingly, no naturally occurring mutations are documented
in any of these potential ERp29 recognition sites. Instead,
many of the documented disease-causing collagen-I mutations
occur in glycine residues that appear at roughly every third
residue in the primary structure and likely interfere with proper
formation of mature collagen’s fibrillar structure. Future study
is not only required to pinpoint the precise binding site of
ERp29 to collagen-I, but more importantly to expand on ERp29’s
stabilizing function in regard to collagen-I formation.

ERp29 as a Regulator of Protein
Assembly
The discussion thus far has focused on ERp29’s role in promoting
the biogenesis of clients, including trafficking of channels
or transporters to the plasma membrane and secretion of
proteins with primarily extracellular functions. Some of these
considerations suggest a role for ERp29 in regulating assembly
of clients into higher order oligomers, which is discussed in
more detail here.

Proinsulin
ERp29’s stabilization of monomeric Cx43 could indicate a
broader role for ERp29 in stabilization of immature proteins
during trafficking. Of particular interest, ERp29 overexpression
appears to stabilize and increase the abundance of intracellular
Proinsulin in models of pancreatic islet β-cells (Viviano et al.,
2020). Like Cx43, Proinsulin is suggested to form hexamers
in the Golgi (Musil and Goodenough, 1993; Kiselar et al.,
2011; Haataja et al., 2013), which are subsequently cleaved
into insulin and C-peptide by furin-like convertases in the
Golgi or later compartments (Smeekens et al., 1992; Nishigori
et al., 1996). Our group has recently demonstrated, using both
MIN6 and INS1 pancreatic beta cells, that ERp29 associates
with Proinsulin, that overexpression of WT ERp29 increases
the intracellular abundance of both Proinsulin and mature
Insulin, and that depletion of ERp29 decreases the intracellular
abundance of Proinsulin (Viviano et al., 2020). On the other
hand, overexpression of the C157S ERp29 mutant increases
the abundance of intracellular Proinsulin but does not result
in a corresponding increase in mature Insulin (Viviano et al.,
2020). These data are consistent with the hypothesis that ERp29
stabilizes intracellular Proinsulin, and that ERp29 promotes
Proinsulin cleavage to Insulin and C-peptide in a manner that
is dependent on its C157 residue. Furthermore, ERp29 appears to
associate with both Proinsulin and the COP II vesicle precomplex
component Sec24D (Viviano et al., 2020), likely as part of larger
complex as Sec24D is cytoplasmic and ERp29 and Proinsulin are
within the ER lumen. These data may suggest a role for ERp29
in promoting Proinsulin’s inclusion in COP II vesicles, possibly

Connexin 43 (Cx43)
Connexins are integral membrane proteins that play a critical
role in intercellular communication by forming gap junctions
that allow ion transfer between adjacent cells, importantly
Ca2+ (Goodenough and Paul, 2003), and have therefore been
implicated in many human diseases (Table 1; Pfenniger et al.,
2011). One of the most ubiquitously expressed Connexin
isoforms is Connexin43 (Cx43), which is highly expressed in the
heart and may play an important role in diseases of myocardial
conduction (Laird, 2008; Das et al., 2009). When forming a Cx43
channel at a tight junction, each neighboring cell contributes
a Cx43 hemichannel that is composed of 6 Cx43 subunits. In
fact, it was initially thought that mutations of the Cx43 gene,
GJA1, would be lethal, given its importance for cardiac function;
however autosomal dominant mutations in GJA1 were recently
linked to oculodentodigital dysplasia (ODDD), a developmental
disorder with some myocardial implications (Paznekas et al.,
2003; Laird, 2008). In addition to forming gap junctions by the
interaction of hemichannels from adjoining cells, Cx43 plays a
critical role in resisting oxidative stress (Kar et al., 2013; Zhao
et al., 2017; Chen et al., 2018) and has been shown to directly
interact with beta-catenin (Spagnol et al., 2018). Therefore,
understanding the critical factors that underlie Cx43 biogenesis
could provide key insights into the underlying pathology of
ODDD and related diseases.
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investigation, and there may be other proteins involved in the
proposed ERp29/KDEL-R/COP II complex yet to be identified.
Furthermore, ERp29 appears to also stabilize immature proteins,
preventing premature oligomerization of Connexin43 (Cx43)
and increasing the intracellular abundance of Proinsulin. ERp29’s
role in protein stabilization prior to full maturation also requires
further interrogation.
ERp29 likely forms large complexes in the ER lumen,
interacting with client proteins, other chaperones, vesicle
adaptors, and receptors such as KDEL-R. The domain structure
of ERp29 is well-delineated, however the contribution of
individual, evolutionarily conserved amino acid motifs to specific
protein–protein interactions has not been fully investigated.
ERp29’s C-terminal KEEL ER retention sequence is one such
motif. Importantly, this ER retention motif is thought to be
“leaky” with regards to ER retention, in that proteins with KEEL
motif are more likely to transverse the Golgi and be secreted
compared to those with the classical KDEL. These data suggest
that ERp29 may have additional function distal to COP II vesicle
fusion with the Golgi membrane; in other words, ERp29 may
also function as a chaperone in the Golgi or later compartments.
However, potential function(s) for ERp29 in Golgi have yet to be
thoroughly interrogated, as well as similar Golgi roles of other
ER-resident chaperones with “leaky” KEEL motifs.
Additionally, ERp29 lacks the classical thioredoxin domain
of most PDI-like ER chaperones; in its place is a single,
evolutionarily conserved cysteine, Cysteine157, which is the
only cysteine in the protein structure. While C157 does not
have a predicted function in client interaction, introducing
a C157S mutation into human ERp29 leads to the loss of
function. Additionally, this Cysteine is located at the base
of ERp29’s D-domain, which is essential for client binding
and processing, and mutation of this Cysteine is predicted to
change the hydrophobicity characteristics of the linker between
b-domain and D-domain, which triggers structural instability of
the D-domain (Hermann et al., 2005). Interestingly, ERp29 in
rats and humans has a longer linker between its two structural
domains as compared to mouse ERp29 and Drosophila Wind,
which could result in higher structural mobility of two domains
in respect to each other in the rat and human proteins. Future
studies should aim to interrogate the mechanistic importance of
both these conserved motifs, as well as effect variations between
species, including the variations in linker length, may have
on ERp29 function.
ERp29 may also play a critical role in ER stress and the
unfolded protein response (UPR), however, its mechanism of
action in this setting is similarly not yet fully elucidated. Like
many ER chaperones, ERp29 expression is upregulated during
ERS and UPR. Although increased ERp29 expression is not
sufficient to induce ERS, its relationship with key ERS sensor
proteins, PERK and BiP, suggest that it may enhance or otherwise
regulate UPR and ERS. However, ERp29’s relationships with
other regulators of ERS has not yet been investigated in depth, nor
has the downstream effect of its relationships with PERK and BiP.
It is therefore important to further interrogate the mechanistic
role of ERp29 in ERS. It is important to note that ERS, its
resolution, and its potential to lead to apoptosis are relevant

via KDEL-R (Grumbach et al., 2014; Bikard et al., 2019; Viviano
et al., 2020). It is thus possible that ERp29 facilitates Proinsulin
processing in a manner that parallels that of Cx43. Specifically,
Ep29 may prevent premature oligomerization of Proinsulin in
the ER and delay the formation of Proinsulin hexamers until
Proinsulin reaches the Golgi.
ERp29’s potential role in the resolution of ERS and UPR is
also of particular interest when considering the pancreatic β-cell.
A healthy ER environment is critical for the maintenance of
functional Islets of Langerhans, and ERS appears to contribute
to the development of Type II Diabetes (T2D) (Sundar Rajan
et al., 2007). Additionally, mutations in the stress responsive
ER resident protein, PERK, previously mentioned as working in
concert with ERp29 to regulate the UPR, cause Wolcott-Rallison
Syndrome, which among other things, results in permanent
neonatal diabetes characterized by low β-cell mass (Senée et al.,
2004; Gupta et al., 2010). It was previously hypothesized that this
phenotype resulted from an impaired ER stress response in the
β-cell, as PERK has been predominantly implicated in UPR and
ERS (Harding et al., 2001). However, recent evidence suggests
that low β-cell mass in the absence of functional PERK is a result
of impaired ER→Golgi transport, resulting in the accumulation
of Proinsulin in the ER and suggesting a role for PERK in
Proinsulin ER exit (Gupta et al., 2010). Additionally, PERK was
demonstrated to co-precipitate with Proinsulin (Gupta et al.,
2010), and, as previously mentioned, co-precipitates with ERp29
as well (Farmaki et al., 2011). As such, PERK’s role in maintaining
β-cell function appears to also implicate it playing a role in
trafficking, perhaps in addition to its more studied role in ERS
and UPR ER. Thus, it is possible that ERp29 and PERK act in
concert to facilitate Insulin biosynthesis in pancreatic β-cells.

DISCUSSION
ERp29 is hypothesized to facilitate the functional processing and
maturation of a diverse range of client proteins implicated in
diseases of protein misfolding or trafficking. However, there are
still critical gaps in our understanding of ERp29’s many and
diverse functions, especially as it relates to these diseases of
protein misfolding or mistrafficking. Because ERp29 is a member
of the PDI/thioredoxin family, but has no thioredoxin activity,
it is hypothesized to function as an escort that facilitates client
export from the ER. While there is still much to learn regarding
ERp29’s mechanisms of action, recent data suggest that ERp29
also promote the inclusion of client proteins in COP II vesicles
for ER→Golgi transport. As ERp29 is an ER luminal protein and
COP II machinery is cytosolic, it is logical to hypothesize that an
integral membrane intermediary must facilitate ERp29’s role to
recruit cargo to COP II vesicles. In fact, our recent data suggest
that the KDEL-R is one such potential intermediate, as it works
in concert with ERp29 to promote the Golgi processing of ENaC.
As the KDEL-R continuously cycles between the ER and Golgi via
COP II and COP I vesicles, respectively, KDEL-R is an attractive
candidate to mediate ERp29’s association with COP II. However,
the ubiquity of the role of KDEL-R in promoting ERp29facilitated cargo recruitment for COP II vesicles requires further

Frontiers in Physiology | www.frontiersin.org

11

September 2020 | Volume 11 | Article 574339

Brecker et al.

Functions of ERp29

to a broad spectrum of diseases ranging from CF and T2D to
cancer and neurodegeneration. As 4PBA upregulates expression
of ERp29, apparently indiscriminate of tissue type, the improved
processing and maturation of a number of proteins with 4PBA
treatment implicate ERp29 and its increased expression levels
as a potentially common mechanism of action. Therefore, it is
logical to investigate ERp29’s relationship with other proteins
whose processing is improved by 4PBA treatment, including
A1AT; ATP-binding cassette proteins ABCA1, ABCA3 and CFTR
(ABCC7); bile salt export pump, BSEP; creatine transporter,
CTR-1; and monocarboxylate transporter, Met8, among others.
In summary, ERp29 is a non-classical molecular chaperone
of the ER that appears to have diverse roles in maintaining
functional and efficient protein processing. Although ERp29 is a
PDI-like protein, it lacks a thioredoxin domain and is therefore
likely redox inactive. In this way, ERp29 is unique, and functions
as a chaperone or escort of immature client protein, stabilizing
clients and facilitating their transport from the ER to the Golgi
for maturation. ERp29 is most highly expressed in secretory
cells, and likely facilitates efficient processing of precursors to
secreted proteins, including Proinsulin, Thyroglobulin (Tg), and
perhaps immature α1-Anti-trypsin (A1AT). However, ERp29
is also ubiquitously expressed in non-secretory tissues and
across organ systems, aiding the maturation of non-secretory
membrane proteins as well, including Cx43 hemichannels or
CFTR and ENaC in epithelial tissue. ERp29 also appears to play
a role in cellular stress processes, including ERS and UPR; and
even has a demonstrated neuroprotective effect. Thus, alterations
in ERp29 function may have implications for cancer cell survival,
β-cell demise in T2D, and neuroprotection in Alzheimer’s and
Parkinson’s diseases. Its significant role in secretory tissue makes
ERp29 a potential target for treatment of A1AT deficiency,
diseases of thyroglobulin processing, and Type 2 Diabetes. ERp29

also rescues the trafficking of the most common CF-causing
mutant, F508del, resulting in functional CFTR protein at the
membrane, and promotes the maturation of functional ENaC.
To summarize, ERp29’s many and diverse roles, as well as its
regulation by 4PBA, make it an attractive clinical target for a wide
range of diseases of protein folding.
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